The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO 2019 | Drug trial updates in multiple myeloma and SMM

Name: Drug trial updates in multiple myeloma and SMM
Uploaded: 2019-06-02T00:00:00.000Z
Duration: 2 min 24 s
Description: Enrique Ocio, MD, PhD, of the University Hospital of Salamanca, Salamanca, Spain gives an overview of key drug trials for multiple myeloma and smoldering multiple myeloma (SMM). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Enrique Ocio • 2 Jun 2019

ASCO 2019

Multiple Myeloma Carfilzomib Daratumumab Dexamethasone Isatuximab Lenalidomide

Enrique Ocio, MD, PhD, of the University Hospital of Salamanca, Salamanca, Spain gives an overview of key drug trials for multiple myeloma and smoldering multiple myeloma (SMM). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.